A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab

NIAID Data Ecosystem2026-03-08 收录

转移性结直肠癌一线治疗

RAS野生型靶向方案比较

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2195502 数据链接链接失效反馈

官方服务：

资源简介：

This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors.

创建时间：

2015-08-15

Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).

转移性结直肠癌一线治疗

肿瘤血管

The PULSAR trial is an international, investigator-initiated, single arm open-label phase II study. The aim of this study is to measure the clinical activity of the combination FOLFIRI-aflibercept in

NIAID Data Ecosystem80

First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer

转移性结直肠癌一线治疗

FOLFOXIRI联合贝伐珠单抗

This is a single-arm, open-label, multicentre phase II study evaluating the safety and efficacy of the combination of the G.O.N.O. FOLFOXIRI regimen with bevacizumab as first-line treatment of metasta

NIAID Data Ecosystem50

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT

转移性结直肠癌一线治疗

舒尼替尼联合FOLFIRI方案

Primary objectives: To demonstrate that the combination of FOLFIRI plus sunitinib is superior to FOLFIRI plus placebo in prolonging the progression-free survival (PFS) in the first-line treatment of p

NIAID Data Ecosystem30

QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety

转移性结直肠癌一线治疗

肿瘤药物临床试验

The purpose of this study is to determine the treatment effect of QL1203 in combination with mFOLFOX6 compared to Placebo in combination with mFOLFOX6 as first line therapy for metastatic colorectal c

NIAID Data Ecosystem70

Capecitabine in combination with Oxaliplatin, Irinotecan and Bevacizumab (COI-B regimen) as First-Line therapy for metastatic colorectal cancer: a Phase II I.T.M.O. study.

转移性结直肠癌一线治疗

COI-B方案临床评价

Primary Objectives Determine the efficacy in terms of : Response rate Safety profile of the COI regimen when administered with bevacizumab Safety profile of bevacizumab when administered after the end

NIAID Data Ecosystem40

A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab

资源简介：

相关数据集